X4 Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:XFOR) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 146.45 M130.01 M105.17 M163.56 M290.46 M Total liabilities 124.3 M107.07 M101.2 M101.94 M104.17 M Total equity 22.15 M22.94 M3.97 M61.62 M186.29 M Total liabilities & shareholders' equities 146.45 M130.01 M105.17 M163.56 M290.46 M Total debt 77.66 M77.41 M77.18 M76.3 M75.99 M Net debt -24.44 M-9.59 M14.18 M-45.91 M-177.01 M

Haberler

Stifel, X4 Pharmaceuticals hissesi için tavsiyesini korudu

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Nadir Hematolojiye Odaklanıyor

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

EMA paneli ultra nadir WHIM sendromu için mavorixafor’u onayladı

EMA panel backs mavorixafor for ultra-rare WHIM syndrome

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy